Comparing Anti-CGRP monoclonal antibodies to OnabotulinumtoxinA for chronic migraine

Migraine Minute News Update

English - May 17, 2024 17:35 - 1 minute - 1.58 MB - ★★★★★ - 3 ratings
Health & Fitness News headache health medical medicine migraine research wellness Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: Can blood flow changes in the eyes explain visual migraine symptoms?

Next Episode: Can This Gepant be an Effective Preventive Treatment Option for Tough to Treat Episodic Migraine?

A new study looks at real-word effectiveness of Anti-CGRP monoclonal antibodies & OnabotulinumtoxinA for chronic migraine. Molly O'Brien will share the study findings in this Migraine Minute News update. Read the study: https://bit.ly/4d1mPx1

*The graphic used in this content is courtesy of Grazzi, L., Giossi, R., Montisano, D.A. et al. Real-world effectiveness of Anti-CGRP monoclonal antibodies compared to OnabotulinumtoxinA (RAMO) in chronic migraine: a retrospective, observational, multicenter, cohort study. J Headache Pain 25, 14 (2024). https://doi.org/10.1186/s10194-024-01721-6. The graphical abstract has been slightly modified.